Related Experiment Videos
Photodynamic therapy for cutaneous proliferative vascular tumors in a mouse model
Maritza A Middelkamp-Hup1, Ignacio Sánchez-Carpintero, Sylvie Kossodo
1Wellman Laboratories of Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
Photodynamic therapy with benzoporphyrin derivative monoacid ring A and red light (PDT-BPD) has been used to treat human choroidal hemangiomas, and may be useful for cutaneous vascular lesions. The potential for PDT-BPD to inhibit selectively vascular tumor growth was tested in a mouse angiosarcoma model, of which the tumor growth mimics the proliferative phase of hemangiomas. Vascular tumors arising after intradermal injection of immortalized murine endothelial cells were exposed to 50 to 150 J per cm2 of 690 nm laser light 15 min after intravenous injection of 1 mg per kg BPD. Tumor volume and gross response were followed after PDT-BPD and compared with control tumors receiving no treatment, light alone, or BPD alone. At 2 wk, hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling stained tumor sections was performed. There was a selective, fluence-dependent inhibition of tumor growth after PDT-BPD (p< or =0.05), typically with eradication of tumors exposed to higher fluences. A common effect was the replacement of tumor by small scar. Surrounding PDT-BPD exposed normal skin showed no changes. Based on these results, we conclude that PDT-BPD can lead to selective eradication of these tumors. Further studies investigating the efficacy of PDT-BPD for human hemangiomas are warranted.
Insights
Photodynamic therapy with benzoporphyrin derivative (PDT-BPD) selectively inhibited vascular tumor growth in a mouse model. This treatment, using red light and a BPD, eradicated tumors, showing promise for hemangioma treatment.
Area of Science:
- Oncology
- Dermatology
- Photomedicine
Background:
- Photodynamic therapy with benzoporphyrin derivative monoacid ring A and red light (PDT-BPD) shows promise for vascular lesions.
- Human choroidal hemangiomas are treated with PDT-BPD.
- Cutaneous vascular lesions may also benefit from PDT-BPD.
Purpose of the Study:
- To evaluate the selective inhibition of vascular tumor growth using PDT-BPD.
- To test PDT-BPD in a mouse angiosarcoma model that mimics hemangioma proliferation.
- To compare PDT-BPD efficacy against control groups (no treatment, light alone, BPD alone).
Main Methods:
- Immortalized murine endothelial cells were injected intradermally to create vascular tumors.
- Tumors were treated with 50-150 J/cm2 of 690 nm laser light 15 minutes after intravenous BPD injection.
- Tumor volume, gross response, and histological changes (H&E, TUNL) were assessed post-treatment.
Main Results:
- PDT-BPD demonstrated selective, fluence-dependent inhibition of tumor growth (p<0.05).
- Higher fluences led to tumor eradication, often replaced by scar tissue.
- Normal skin surrounding treated areas showed no adverse effects.
Conclusions:
- PDT-BPD can selectively eradicate vascular tumors.
- The findings support further investigation of PDT-BPD for human hemangiomas.
- PDT-BPD is a promising therapeutic strategy for vascular tumors.